Researchers are actively recruiting for a Phase I/II clinical study of an enhanced, more bioavailable formulation of saquinavir (Invirase), the protease inhibitor drug from Hoffmann-La Roche.
About 90 people are needed at 10 U.S. medical centers for a dose-ranging study comparing 2 formulations of Invirase.
Participants will be randomized to 1 of 4 monotherapy treatment arms for 8 weeks. Afterwards, participants can continue on saquinavir plus the anti-HIV treatment of their choice. Trials are enrolling in Jefferson County, AL; Boston, MA; Jackson County, MO; New York, NY; Portland, OR; and Galvetson, TX. For more information about the study, call Roche at 1-800-526-6367 or 1-800-TRIALS-A.